VMD-928

Overview

VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A ( TrkA ) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA , thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer , thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer , hepatocellular carcinoma.

Application

Products | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Trk Receptor

Product Information

• Catalog No.: HY-171450
• CAS No.: 1802770-18-8
• Molecular Formula: C31H32N4O4
• Molecular Weight: 524.61
• Purity: 98.12%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source